Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
38 results about "Trypanosoma cruzi" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Trypanosoma cruzi is a species of parasitic euglenoids. Amongst the protozoa, the trypanosomes characteristically bore tissue in another organism and feed on blood (primarily) and also lymph. This behaviour causes disease or the likelihood of disease that varies with the organism: for example, trypanosomiasis in humans (Chagas disease in South America), dourine and surra in horses, and a brucellosis-like disease in cattle. Parasites need a host body and the haematophagous insect triatomine (descriptions "assassin bug", "cone-nose bug", and "kissing bug") is the major vector in accord with a mechanism of infection. The triatomine likes the nests of vertebrate animals for shelter, where it bites and sucks blood for food. Individual triatomines infected with protozoa from other contact with animals transmit trypanosomes when the triatomine deposits its faeces on the host's skin surface and then bites. Penetration of the infected faeces is further facilitated by the scratching of the bite area by the human or animal host.
Geldanamycin derivatives and method of use thereof
The present invention relates to novel geldanamycin derivatives which have antitumor and antiparasitic properties. The geldanamycin derivatives disclosed herein have antitumor properties in humans due to their interaction with human heat shock protein 90 (hsp90). The human parasites Plasmodium falciparum, Trypanosoma Cruzi, and Leishmania donovani are lethally susceptible to exposure to geldanamycin via complexation of geldanamycin with their homologs (Pfhsp90, hsp83, and hsp90, respectively) of the human hsp90. The geldanamycin derivatives disclosed herein also interact with these parasitic hsp90 homologs so as to have antiparasitic properties.
Owner:BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIV
Nitroimidazole compounds
InactiveCN101341150AAntibacterial agentsOrganic active ingredientsNitroimidazoleCombinatorial chemistry
The present invention relates to certain nitroimidazole compounds, which have interesting pharmaceutical properties. In particular, the compounds are useful in the treatment and / or prevention of infections such as those caused by Mycobacterium tuberculosis, Trypanosoma cruzi or Leishmania donovani. The invention also relates to pharmaceutical compositions containing the compounds, as well as processes for their preparation.
Owner:NOVARTIS AG +1
Trypanosoma cruzi proteome compositions and methods
Molecular targets are identified in T. cruzi suitable for use in diagnosis of Chagas disease, drug development, and vaccines, including live vaccines.
Owner:GEORGIA RESERACH FOUND INC UNIV OF
Antigens and immunoassays for diagnosing Chagas' disease
Owner:INNOGENETICS NV
Antigens and immunoassays for diagnosing Chagas' disease
Transfusion of contaminated blood has become the major route of transmission for Chagas' disease. Current screening tests are insensitive and yield conflicting results, while confirmatory assays do not exist. The present invention relates to antigens and their use for serological diagnosis of Chagas' disease. More specifically, the present invention concerns assays which are able to reliably and accurately detect the presence of antibodies to various specific antigens of Trypanosoma cruzi in a highly sensitive and specific manner.
Owner:INNOGENETICS NV
Prophylactic and therapeutic immunization against protozoan infection and disease
InactiveUS7309784B2Convenient introductionIncrease stimulationBiocideProtozoa antigen ingredientsProtozoaMammal
Owner:UNIV OF GEORGIA RES FOUND INC
Flavin protein of trypanosoma cruzi, method of screening vermicide with the use of the same and diagnostic
InactiveUS20060275329A1Promote decompositionHighly specific and simple methodCompound screeningApoptosis detectionFlavoproteinTrypanocidal Drugs
It is intended to provide a method of diagnosing infection with Chagas disease by screening a trypanocidal drugs for Trypanosoma cruzi which is the pathogen of Chagas disease. Using a flavin protein TcOYE specific to Trypanosoma cruzi, a trypanocidal drugs effective against Trypanosoma cruzi is screened. Using the gene sequence of TcOYE and an antibody therefor, infection with Trypanosoma cruzi is diagnosed.
Owner:OSAKA BIOSCI INST +1
Multicomponent or monocomponent vaccine to be used against Chagas disease, pharmaceutical compositions containing them, procedure for the obtention of immunogen of said vaccines, and nucleic acid used in said procedure
InactiveUS8900598B2Stimulate immune responseEliminates itAntibacterial agentsPeptide/protein ingredientsChagas diseaseTrypanosomiasis
Owner:DE BAEREMAECKER BARROS CARLOS
Parasite detection kit and detection method thereof
InactiveCN108588252AHigh sensitivityLow costMicrobiological testing/measurementAgainst vector-borne diseasesNucleotideLeishmania mexicana
The invention relates to the field of parasite detection, and discloses a parasite detection kit and a detection method thereof. A nucleic acid reaction system of the parasite detection kit internallycomprises one or more nucleic acid amplification primer pairs for amplifying nucleotide sequences of DNA of trypanosome, leishmania, leishmania braziliensis, chagasi leishmania, Trypanoma cruzi, Trypanoma rangeli, leishmania, leishmania mexicana or leishmania amazonensis, panamensis leishmania donovani, guyanensis leishmania, or peruviana leishmania. The detection method comprises the steps thatthe one or more nucleic acid amplification primer pairs are used for a nucleic acid amplification reaction, and existence of the DNA of parasites is detected by detecting specific amplicons of the nucleic acid amplification primer pairs. Compared with a PCR, detecting through a RPA amplification mode is conducted in constant-temperature and simple equipment, the cost is low, the sensitivity is high, the parasite detection kit can be used for diagnosis of the trypanosome and the leishmania for early-infected people and infected dogs, and thus the VL incidence rate in human bodies is decreased.
Owner:杭州泰熙生物技术有限公司
Multicomponent or monocomponent vaccine to be used against chagas disease, pharmaceutical compositions containing them, procedure for the obtention of immunogen of said vaccines, and nucleic acid used in said procedure
InactiveUS20100297186A1Stimulate immune responseReduces clinical consequenceAntibacterial agentsProtozoa antigen ingredientsChagas diseaseTrypanosomiasis
A vaccine against the Chagas disease, capable of stimulating the immune response against the trans-sialidase virulence factor of the Trypanosoma Cruzi parasite, which is a multicomponent vaccine comprising: (a) an immunogenic portion formed by one or more recombinant or synthetic polypeptides or fractions of thereof and (b) one or more polynucleotides including the regions that codifying one or more immunogenic polypeptides, or a monocomponent comprising at least one component selected among an immunogenic portion formed by one or more recombinant or synthetic polypeptides or fractions of them and a group of polynucleotides including the regions codifying one or more immunogenic polypeptides derived from Trypanosoma Cruzi and pharmaceutical compositions containing said multicomponent and monocomponent vaccines, the procedures for obtaining the immunogen portion of said vaccines and the nucleic acid used in the procedure.
Owner:DE BAEREMAECKER BARROS CARLOS
Reagent combination and kit for detecting blood transfusion transmitted pathogens and application
PendingCN111286557ARich varietyFull rangeMicrobiological testing/measurementMicroorganism based processesWhole blood productBlood product
The invention discloses application of a reagent combination for detecting pathogens in preparation of a kit for detecting the quality of a blood product. The pathogens are selected from a pathogen group consisting of HAV, HBV, HCV, HEV, TP, HIV1, HIV2, HTLV1, HTLV2, HBOV, TTV, HCMV, B19, DENV, ZIKV, WNV, babesia, trypanosoma krusei and plasmodium, and belongs to the field of medical examination.The invention further discloses a corresponding kit and a method for detecting the quality of the blood product. By means of the kit, the lowest detection limit of pathogens is 1.0 * 10 < 3 > copies / mL, the kit has good specificity and repeatability, and an important technology is provided for screening and evaluating blood transfusion transmitted pathogens.
Owner:山西国际旅行卫生保健中心
Organic compounds
Owner:NOVARTIS AG
Organic compounds
The invention relates to organic compounds which have interesting pharmaceutical properties. In particular, the compounds are useful in the treatment and / or prevention of infections such as those caused by Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale, Trypanosoma cruzi and parasites of the Leishmania genus such as, for example, Leishmania donovani. The invention also relates to pharmaceutical compositions containing the compounds, as well as processes for their preparation.
Owner:NOVARTIS AG
Trypanosoma cruzi proteome compositions and methods
Owner:GEORGIA RESERACH FOUND INC UNIV OF
Nitroimidazooxazine and nitroimidazooxazole analogues and their uses
The current invention pertains to nitroimidazooxazine and nitroimidazooxazole analogues, their methods of preparation, and uses of the compounds as treatment for Mycobacterium tuberculosis, for use as anti-tubercular drugs, for use as anti-protozoal agents with unexpectedly high potency against Trypanosoma cruzi or Leishmania donovani, and for the treatment of other microbial infections.
Owner:GLOBAL ALLIANCE FOR TB DRUG DEV (US)
Recombinant trypanosoma cruzi cells useful as Anti-cancer immune agents
Recombinant, attenuated parasites are transformed or transfected with nucleic acid molecules which provoke an immunostimulatory and protective response in subjects. Preferably, the parasite is Trypanosoma cruzi, especially strain CL-14, and the transforming nucleic acid molecule encodes for a cancer testis antigen, such as NY-ESO-1.
Owner:LUDWIG INST FOR CANCER RES +1
Nitroimidazole Compounds
InactiveUS20080275035A1Maintain good propertiesAntibacterial agentsOrganic active ingredientsNitroimidazoleCombinatorial chemistry
The present invention relates to certain nitroimidazole compounds, which have interesting pharmaceutical properties. In particular, the compounds are useful in the treatment and / or prevention of infections such as those caused by Mycobacterium tuberculosis, Trypanosoma cruzi or Leishmania donovani. The invention also relates to pharmaceutical compositions containing the compounds, as well as processes for their preparation.
Owner:JIRICEK JAN +4
Specific primers, probe, kit and chip for Trypanosoma gene detection
PendingCN110964843AEasy diagnosisFacilitate Disease SurveillanceMicrobiological testing/measurementDNA/RNA fragmentationTrypanosoma brucei gambienseTrypanosoma gambiense
The invention provides specific primers for the detection of Trypanosoma cruzi with the sequences as shown in SEQ ID No.1 and SEQ ID No.2, provides specific primers for the detection of Trypanosoma brucei with the sequences as shown in SEQ ID No.3 and SEQ ID No.4, provides specific primers for the detection of Trypanosoma brucei rhodesiense with the sequences as shown in SEQ ID No.5 and SEQ ID No.6, provides specific primers for the detection of Trypanosoma brucei gambiense with the sequences as shown in SEQ ID No.7 and SEQ ID No.8, provides a probe for the detection of Trypanosoma with the sequences as shown in SEQ ID No.9 to 26, and also provides a kit and a chip for the detection of Trypanosoma. In the invention, differential diagnosis for Trypanosoma infection can be specifically carried out.
Owner:中国疾病预防控制中心寄生虫病预防控制所国家热带病研究中心
Trypanosoma cruzi antigen, gene encoding therefor and methods of detecting and treating chagas disease
InactiveUS6933110B1Improve presentationImprove stabilitySugar derivativesMicrobiological testing/measurementAntigenTrypanosoma antigen
The nucleotide sequence of Tc100, a gene encoding PTc100, a new Trypanosoma antigen, and the amino acid sequence of PTc100 are described. Tc100 and PTc100, or fragments thereof, modified or otherwise, can be used directly or indirectly for the detection of Trypanosoma cruzi, or for the monitoring of the infection generated by Trypanosoma cruzi, in man or in animals.
Owner:BIOMERIEUX SA
Method for inhibiting Trypanosoma cruzi
Owner:HOWARD UNIVERSITY
Mucin-associated surface protein as vaccine against Chagas disease
Use of synthetic peptides derived from Trypanosoma cruzi antigens and their use in vaccination against trypomastigote infection and Chagas disease. T. cruzi uses several surface proteins to invade the host. In their role of protection, the surface protients ensure the targeting and invasion of specific cells or tissues. A conserved region in the family of mucin-associated surface proteins (MASP) was used to analyze the expression of MASP at different points of invasion and proved to be important for host cell invasion, thus suggesting MASP as a candidate for vaccine development. A synthetic peptide, MASPsyn, was studied and showed efficacy in stimulating antibody and cytokine production necessary for resistance against the parasite.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
A bacterial surrogate for testing of antimalarials: thya knockout, fola knockout, folp knockout, and folk knockout bacteria for testing of inhibition of antifolate pathway
ActiveUS20160230178A1Microbiological testing/measurementBiological material analysisBacteroidesAntibiotic resistance
In this invention, cell lines are created for enzyme inhibitory testing of inhibitors against Plasmodium falciparum DHFR-TS and HPPK-DHPS. Provided the complementing DHFR-TS and HPPK-DHPS have sufficient activities to support growth of the surrogates in un-supplemented medium, the same surrogates could be used for screening inhibitors of targets against other parasite and pathogen species e.g. Plasmodium vivax, Trypanosoma brucei, Trypanosoma cruzi, Toxoplasma gondii or Mycobacterium tuberculosis. The cell lines in this invention are Escherichia coli strain whose thyA, folA, folK, and folP genes were disrupted using genetic knockout coupled with elimination of antibiotic resistance markers. The thyA KO, folP KO, folK KO, thyAfolA KO, folKfolP KO, thyAfolAfolP KO, thyAfolAfolK KO and thyAfolAfolKfolP KO E. coli cell lines are easy and convenient for testing single and combination drugs as plasmids bearing complementing parasite genes can be introduced simply by transformation using standard antibiotic selection.
Owner:NAT SCI & TECH DEV AGENCY
New pradimicin derivatives for the treatment of diseases caused by kinetoplastids
ActiveUS20160243140A1Reduce usageUseful in treatmentOrganic active ingredientsAntiparasitic agentsDiseaseChagas disease
The present invention relates to a class of novel pradimicins and analogues and derivatives thereof, including the compounds of formula A, I and 111, and / or a pharmaceutical acceptable addition salt thereof and / or a stereoisomer thereof and / or a solvate thereof and their use to treat or prevent kinetoplastid infections and their use to manufacture a medicine to treat or prevent kinetoplastid infections, particularly infections with trypanosoma and leishmania, such as Trypanosoma brucei, Trypanosoma cruzi and Leischmania donovani. wherein Ra, R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the claim 1 or as described in detail in the description of the invention. The present invention also relates to pharmaceutical compositions of said compounds and the use of said pharmaceutical compositions to treat or prevent kinetoplastid infections. The present invention further relates active ingredients, more specifically as medicaments for the treatment of kinetoplastid infections and pathologic conditions such as, but not limited to Trypanosomiasis, such as African trypanosomiasis, sleeping sickness, Chagas disease and leishmaniasis.
Owner:KATHOLIEKE UNIV LEUVEN +1
Method for inhibiting trypanosoma cruzi
Methods are provided to inhibit proliferation of Trypanosoma cruzi with imido-substituted 1,4-naphthoquinones, including novel compounds. Administering an imido-substituted 1,4-naphthoquinone can be used to provide prophylaxis or treatment to a patient in need of treatment against Chagas disease.
Owner:HOWARD UNIVERSITY
Charge Gradient Inhibition of Trypanosoma Cruzi and Other Parasite's Invasive Action
InactiveUS20080248091A1Preventing and delaying and symptomReduce in quantityPowder deliveryProtozoa antigen ingredientsDiseaseNanoparticle
Methods for delaying and / or preventing the binding of parasites to host cells (especially mammalian host cells) are provided. The methods delay or prevent infection of host cells and the development of disease symptoms. The methods delay or prevent the parasites from locating and binding to host cells, thereby reducing the infectivity of the parasite, and allow for adjuvant drug therapy to have a longer treatment time period before infection sets in. The methods involve modifying the charge field sensed by the parasite in the vicinity of potential host cells. Such modifications may be made by exposing the parasite and / or the host cell to charge-altering agents such as charged nanoparticles.
Owner:VIRGINIA COMMONWEALTH UNIV
Anti-parasitic compounds and uses thereof
ActiveUS11180492B2Good curative effectDelay moreOrganic chemistryAntiparasitic agentsAntiparasiticProtozoa
The present disclosure provides compounds of Formula (I′), Formula (II), and Formula (III). The compounds described herein may useful in treating and / or preventing protozoan infections in a subject in need thereof, treating and / or preventing trypanosomal infections (e.g., Trypanosoma cruzi (T. cruzi) or Trypanosoma brucei infections) and / or plasmodial infections in a subject in need thereof, treating and / or preventing diseases in a subject in need thereof (e.g., Chagas disease, malaria, and / or sleeping sickness), and may be useful in treating and / or preventing infectious diseases in a subject in need thereof. Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including a compound described herein.
Owner:RGT UNIV OF CALIFORNIA +3
Escherichia coli cell line with thyA knockout, folA knockout, and one or both of folP knockout, and folK knockout
ActiveUS10011842B2Microbiological testing/measurementBiological material analysisAntibiotic resistanceDHPS
Owner:NAT SCI & TECH DEV AGENCY
Mucin-associated surface protein as a vaccine against chagas disease
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Anti-parasitic compounds and uses thereof
ActiveUS20190002463A1Good curative effectConvenient treatmentOrganic chemistryAntiparasitic agentsAntiparasiticProtozoa
The present disclosure provides compounds of Formula (I′), Formula (II), and Formula (III). The compounds described herein may useful in treating and / or preventing protozoan infections in a subject in need thereof, treating and / or preventing trypanosomal infections (e.g., Trypanosoma cruzi (T. cruzi) or Trypanosoma brucei infections) and / or plasmodial infections in a subject in need thereof, treating and / or preventing diseases in a subject in need thereof (e.g., Chagas disease, malaria, and / or sleeping sickness), and may be useful in treating and / or preventing infectious diseases in a subject in need thereof. Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including a compound described herein.
Owner:RGT UNIV OF CALIFORNIA +3
Nitroimidazoxazines and analogs of nitroimidazoxazoles and uses thereof
Owner:GLOBAL ALLIANCE FOR TB DRUG DEV (US)
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com